Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2017–2021

PAIN-Net · Molecule-to-man pain network

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2017-02-01 → 2021-07-31
Финансиране от ЕС
3 335 316 €
Участници
13
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Генетичните и молекулярни причини за невропатичната болка се анализират чрез изучаване на натриевите канали и протеомика. Това помага за по-доброто разбиране на индивидуалната чувствителност към болката и ефективността на лекарствата при пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Molecule-to-man pain network

Neuropathic pain affects 5% of the general population and 40% of patients with neurological diseases, and has a key role in the pathophysiology of cancer pain that affects up to 50% of patients in the early disease stage and 30% of survivors, causing an enormous social burden. Treatments are inadequate with less than 50% of patients achieving 50% of pain relief at best, while up to 30% of cancer pain patients experience insufficient analgesia. Signatures of individual susceptibility to pain and analgesic responsiveness are urgently needed to improve patients’ management. Such advances are expected to originate from integrated clinical, basic science and entrepreneurial research readily translating scientific findings into benefits for patients. To consolidate these aims, a new generation of scientists with wide knowledge in neuropathic pain, focused research skills and experience in the interaction with biotechnology companies is needed. The PAIN-Net programme has supported such talented and inspired early stage researchers. Their research projects, embedded in an advanced molecule-to-man pain network, contributed to better understanding individual susceptibility to pain and analgesics responsiveness based on next generation sequencing, whole exome sequencing, epigenetics and pharmacogenomics studies, nociceptor and sodium channel functioning based on biophysics and proteomics studies, targeted analgesics based on high-throughput screening, and on the development and characterization of the first mouse models of sodium channel-related neuropathic pain.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Neuropathic pain affects 5% of the general population and 40% of patients with neurological diseases, and has a key role in the pathophysiology of cancer pain that affects up to 50% of patients in the early disease stage and 30% of survivors, causing an enormous social burden. Treatments are inadequate with less than 50% of patients achieving 50% of pain relief at best, while up to 30% of cancer pain patients experience insufficient analgesia. Signatures of individual susceptibility to pain and analgesic responsiveness are urgently needed to improve patients’ management. Such advances are expected to originate from integrated clinical, basic science and entrepreneurial research readily translating scientific findings into benefits for patients. To consolidate these aims, a new generation of scientists with wide knowledge in neuropathic pain, focused research skills and experience in the interaction with biotechnology companies is needed. The PAIN-Net programme, based on a highly innovative platform of training-through-research and strongly committed to such objectives, will support such talented and inspired early stage researchers. Their research projects, embedded in an advanced molecule-to-man pain network, will contribute to better understanding individual susceptibility to pain and analgesics responsiveness based on next generation sequencing, whole exome sequencing, epigenetics and pharmacogenomics studies, nociceptor and sodium channel functioning based on biophysics and proteomics studies, targeted analgesics based on high-throughput screening, targeted analgesic delivery based on encapsulated cell bioreactor implants, and to the development and extensive characterisation of the first knock-in mouse models of sodium channel-related neuropathic pain based on the CRISP-Cas technology. Most of all, the PAIN-Net programme will offer the unique opportunity to enhance scientific capabilities and prepare to high level academic or private applied research career.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз